Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning, everyone, and thank you for dialing in to the Q2 2026 earnings call for the Vitrolife AB Group. I would like to start with three key highlights in the quarter. We delivered record revenue of 358 MSEK in consumables, which represents 15% organic growth in our Americas region, a net income of 129 MSEK, and an EPS of 0.956. We also launched EmbryoCath and EmbryoViewer Pro. So for the first time, we can compete in the embryo transfer segment. EmbryoViewer Pro, which we recently showcased at the ESHRE Congress, is an advanced software program for our EmbryoScope time-lapse system. I will now move us on, and I would like to provide you with an overview of the market in each of our regions, starting with EMEA. European IVF cycle activities appear to be at normal levels. However, in the region, the Middle East crisis is impacting IVF cycles significantly. We do not. In the Vitrolife AB group, we do not see Middle East distributors restocking at this time. In fact, the airspace has been regularly closed. So even shipping goods into the region is a challenge. In the APAC region, which I recently visited myself, we see that IVF cycles in China are declining year over year. This trend is expected to continue based on population demographics. Southeast Asia within the APAC region is growing as access increases in Japan and Korea. The combined markets are growing in the low single digits. Although the birth rate in Korea has rebounded significantly in 2026, with total fertility increasing above 0.9 for the first time in many years. So one could reasonably expect a pickup in cycles in South Korea. In the Americas region, if we look at the US, cycle activity was very slow at the start of Q2. Specifically in April and May. But it started to pick up in the month of June. There were wide variations between the US states, with wealthier areas like Massachusetts, New York, and Southern California performing stronger. In South America, we see an increased presence of low-cost generic competitors in genetics. Cycle activity remains robust in the Americas region, specifically within South America. Okay, so moving on to look at the performance in our largest region, EMEA, which accounts for 37% of our global revenue, as is evidenced from our donut chart here on the right-hand side of the slide. We delivered 1% organic growth in local currencies, excluding the exited business of NIDA and GDPS. Western Europe remained strong. However, IVF cycles, as I've just mentioned, are significantly down in the Middle East, and this weighed on the regional performance. Consumables grew 4% in local currencies, with Europe performing well and the Middle East behind prior year. Technologies increased 3% in local currencies with installs in Europe offset by low capital demand in the Middle East. And we are also seeing positive trends month after month in the consumable revenue stream from our EmbryoScope systems. Genetics decreased by 3% with the Middle East volumes down substantially. We've been focusing on driving margin improvement in all regions, so it's very pleasing to see the positive trend in our gross margin. So if you just look at the chart for the first time, you won't have seen this in previous slides that I've presented, but we have added the gross margin trend. And what you see here is a two percentage point improvement in gross margin, primarily driven in the case of EMEA by the exit of non-core assets and GDPX, and also our operational efficiency program, which we have been focusing on across the Vitrolife AB group. We will now move on and look at the Americas. In the Americas region, we delivered 1% organic growth in local currencies. The share of revenue coming from Americas now stands at 34%. As you can see here in the donut on the right-hand side, North America performed well across the portfolio. You know that this is one of our key focus markets. We have been doubling down here for a couple of years now. South America's exit from low-profit genetic accounts reduced top-line growth, but it improved regional profitability. Consumables increased by 15% in local currencies, with significant gains in media in North and South America. We are delighted with these wins because we've really doubled down to take share here, and I want to thank my team for their huge efforts in bringing these wins over the line. Time-lapse decreased by 9% due to a large capital deal with a clinic chain in the same quarter last year, which most of you will likely remember. South America had a very strong capital sales quarter. As we increase our focus on EmbryoScope, we are both increasing the penetration of the capital systems and the utilization of those EmbryoScope units, while Genetics decreased by 3% with continued growth in our key focus market of North America, offset by the exit of low profit accounts in South America. This is a strategic decision as we do not want to compete in low-profit segments. We are a premium service, differentiated company with best-in-class technology and genetics, and we will not follow low-price generic competitors. A 3.6 percentage point improvement in our gross margin. And this is really down to our increased focus on consumables in the Americas. Again, this is a strategic decision to focus on this area. And we believe we have further opportunities in consumables and in technologies, particularly in South America, but also in North America. Okay, we will now finally move on to the APAC region, where we had a decline of 1% organic growth in local currencies. APAC now accounts for 29% of our global revenue. I am delighted to report that Japan delivered strong growth, our best in several years. In fact, we continue to expand our share across the portfolio in Southeast Asia. However, as I have mentioned, demand in China slowed further as the quarter progressed. Sales in consumables decreased by 5% with a strong performance in Southeast Asia and Japan, offset by weak demand in China. Technologies increased by 6%, primarily driven by capital sales in Japan. This is particularly pleasing to see because Japan is a highly penetrated market for EmbryoScope. A big call out to our Japan team for the really nice job that they have done. Their genetics increased by 2% across the region, so slightly above the regional growth rate for APAC at present, a 1.4 percentage point increase in gross margin driven by price increases and operational efficiency. The team on the ground has done a really nice job here, so driving price gains in a very competitive market is not an easy thing to do. And I think the Vitrolife AB group APAC team have done a really nice job here. Okay, so I'll move on to the final slide, my final slide, at least before I hand over to Pär. As you know very well by now, the Vitrolife AB group has a mission to be the leading global partner in reproductive health, striving for better outcomes for patients. We focus on three key areas to get to that coveted number one spot. They are growth, innovation and operational excellence. So how are we doing? Are we advancing in these key areas? So when it comes to growth, we are driving profitable growth through improved market and customer segmentation. I believe you can really see this in this quarter. We are doubling down on the markets, on the areas of the portfolio, and on the customers where Vitrolife AB group can drive profitable growth. We are gaining share in consumables. This represents 15% organic growth in the Americas for media. That is well above the growth rates there. And we are increasing the penetration and utilization of EmbryoScope. We are also building out our platform solution with the combination of EmbryoScope and eWitness in relation to innovation. We are not just talking about innovation. We have delivered. We launched EmbryoCath and EmbryoViewer Pro, which we showcased at ESHRE. However, we also have more launches planned in the coming quarters, and I really want to thank our R&D and innovation teams for the work that they have been doing there. We are also advancing the efficiency of IVF clinics, partnering with our customers, and driving the use of AI in embryo selection. When it comes to operational excellence, we continue to invest in digital capabilities to improve the customer journey and our connectivity with clinics. We have taken actions, and you can see this in our quarterly results. We have taken actions to optimize our cost base across operations and back office. So we are doing what we said we would do when it comes to our restructuring program. So I would say in summary, we are advancing our mission and we are doing it in a profitable, sustainable way. I will now hand you over to Pär, who will take you through the key financials.
Thank you, Bronwyn. So let's start with just some more information on the geographic segments. Bronwyn just went through the slides explaining sales, gross income, and gross margin. I just want to add the market contribution. We saw the same pattern there as in the gross margin improvements in all regions and also for the total. And so America ended up at a gross contribution margin of 33.8%, an improvement of more than 4 percentage points compared to quarter two last year in EMEA. 39.4% compared to 35% last year, and then APAC, 44% compared to 41% last year, and in total then for Vitrolife AB Group, 38.8% compared to 34.7%. So the market contribution is, of course, improved. Part of it is the improved gross margin, but also the reduction in OpEx related to sales and marketing costs. Moving to the next slide. So the highlights then: the net sales ended up at 857 million SEK. That represents -2% growth in SEK. I will come back to more details on net sales on the next slide. Our gross income was 517 million SEK, which represents a margin of 60.3%, almost 2 percentage points improvement from last year, and then an EBITDA of 295 million SEK, equal to an EBITDA margin of 34.4%, compared to 27.8% in the quarter. We had, of course, the effect of this strong gross margin, but also we are working hard on the cost reduction program. But we also have some one-time items in the quarter amounting to 13 million SEK. So the split on the sales development, the -2% growth in SEK is explained by an organic growth of 1%. But then we have the exit of the NACE and GDPX business, which had full effect in the second quarter, representing -2%. And then we still have a negative currency impact on the top line, although it is much less now. It is only 1% now, so that is good. So all in all. This explains the 2% negative growth in SEK. Let's have a closer look at the gross margin development over the last five quarters. Strong development with a 2.3 percentage point improvement from Q2 last year. It is a result of our strategic decision to focus on higher margin products and markets. We see an improved gross margin in all regions and all product groups. A minor positive effect also comes from the mix. Coming from that, we have growth in consumables, flat in technologies and negative growth in genetics. So we have also a positive mix effect in the quarter. Okay. And then if we have a closer look at the operational expenses for the last five quarters, we have a reduction of 48 million SEK compared to Q2 last year. So we continue to see the reduction that we have had now for three quarters in a row. It reflects the positive impact of the ongoing restructuring program and continued cost discipline. But also, as I mentioned, we have a positive one-time effect amounting to 30 million, primarily driven by VAT accrual release. But also in the quarter, we had a positive currency revaluation effect of 8 million SEK. It was minus 5 million SEK in Q2 of last year. So it is a 13 million SEK swing there. And on the cash flow. Our cash flow for the quarter amounted to 140 million, compared to 151 million in Q2 last year. We had a negative impact from the build-up of working capital, mainly driven by an increase in our operating receivables. But also, we built up inventory ahead of the vacation period. And then a summary of the key financials, sales 871 million SEK, with 857 million SEK in Q2, gross margin 60.3%, and EBITDA 295 million SEK. Strong EBITDA margin of 34.4%. Net income was 129 million SEK compared to 100 million SEK in Q2 last year, and our earnings per share was 0.95 SEK compared to 0.74 SEK last year in Q2. And our operating cash flow was 140 million compared to 151 million. And our net debt to EBITDA ratio ended up at 0.7 compared to 0.9. Okay. And then, I also mentioned yesterday that the board approved a share repurchase programme. This was communicated through a press release yesterday evening. It is a program to repurchase shares up to a maximum of 500 million SEK starting tomorrow until the AGM 2027. This program aims to optimize the capital structure and enhance shareholder value. The repurchase will be made on Nasdaq Stockholm, in line with applicable regulations, and treasury shares may not exceed 10% of outstanding shares, and this repurchase program is in addition to the Vitrolife AB Group dividend policy. The AGM on the 5th of May 2026 approved a dividend of 1.10 SEK per share, totaling 149 million SEK for full year 2025. So that was my last slide. So we open up for Q&A.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. Please start by asking one question followed by a follow-up question. It is then fine to queue up again for more questions. The next question comes from Ludvig Svensson from Handelsbanken. Please go ahead.
Yes. Good morning, and thank you for taking my question. So I will keep it to one as requested. I want to keep it to genetics just to make sure we get things right. You mentioned how the genetics XXL tests are impacting the group development. But if you break it down and focus just on genetics development, how do you see things moving following the exits of the tests and how do you see things progressing going forward?
Thank you for your question, Ludwig. I just want to make sure that I understand it. So having exited the PGT-A and PGT-P tests, how do we see the genetics business going forward? Is that correct?
Yes, exactly. So, yes. So for the remainder of what was left, basically.
Yeah. Obviously, we have completely exited those two tests. Now, most of the revenue came from that region. So that is the region that has been most impacted by this exit. But as is also evidenced in South America, we are also exiting low profit accounts. So, in certain parts of the world, primarily in Latin America, we see an increase in generic competition with very low prices. We are not going to play in low-cost generic segments. So we have been exiting certain accounts in that region as well. It has had a top-line impact in the quarter, but it improves our profitability. And I think strategically going forward, we will continue to do that. So if we see an opportunity to improve the profitability of our business and it does not make sense to stay in lower profit accounts. We will continue to do that. So we are very much doubling down on driving profitable growth across all portfolios. The main areas where we have lower profit accounts are on the genetics side. So we will continue to do portfolio or I guess account rationalization is probably the best way to do that going forward. It benefits our profitability. It allows us to focus on driving growth in the more profitable parts of the portfolio. Pat. I don't know if you would know anything about that.
You summarized it well there.
Do you have a follow-up question? Yeah.
Yes, please. I want to stay on genetics. And we are talking about profitability. I know that you don't disclose divisional profitability, but given that there are things to improve profitability. Could you provide any further color on how we should think about genetics profitability and how it will move following this, or is it possible to comment on that?
Yeah. Well, what we can say, which I also mentioned in previous calls, is that we increased our focus and our ability to analyze profitability on a customer level and market level to help us guide which accounts and which markets we should focus on and which ones we should not. So we have increased our toolbox and our competence and focus in this area to drive profitable growth. And that will continue. We will continue to work on this in order to improve our profitable growth journey.
Okay. Great. Thank you for taking my question.
Thank you, Ludwig.
The next question comes from Jakob Lemke from SEB. Please go ahead.
Yes. Good morning. My question relates to the Middle East, and I am wondering if you can comment on roughly how much it has declined in the quarter. And also, are you able to decipher any trends in either direction? Yeah. In the recent weeks or months.
Yeah. So, good morning, Jakob. Thank you for your question. We do not divulge Middle East revenue or percentage decline. But it is significant, and it has been significant since the start of this war. I guess if we are calling a spade a spade, this is a war. What I would say is that when the negotiations between the US and Iran seemed to be going well. There was a slight pickup in June and people were feeling more positive. But of course, we have seen a reverse in that trend in the past couple of days. I know the market receives very mixed messages on the Middle East. The reality is that we see cycles are significantly down across the entire Middle East region. The airspace has been closed on and off. And obviously, it is not just Iran or UAE. It's Bahrain, it's Iraq. It is very difficult to even do business in that region right now. Based on what we saw in June, if a deal can be reached between the Iranians and the Americans and the Strait of Hormuz opens back up, we feel that the cycles would return to normal levels. I don't want to say quickly, but the demand is there. The problem is, doing business is extremely difficult. So, the sooner we have peace and an agreement, I think the faster the region can get back to growing again. But it is in negative territory right now. The cycles are down significantly versus last year. And we see that in all clinics. Yeah. So it is a very difficult question to answer. Jacob. I am not trying to be evasive, but it depends on factors outside of our control, I am afraid.
Okay, that's fair enough. And my follow-up question is on Europe, which you say is strong. Is that you know, that you are growing slightly above the cycle growth rate, or is it substantially above the cycle growth rate? Would you say?
I would say it is above the market growth rate. I wouldn't say it's substantially above, but we are growing above the market in Europe. Yeah.
Okay.
That is our stronghold. That's our stronghold. And we intend to keep it.
Good. I will return to the queue and come back.
Thanks, Jacob.
The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.
Hi. Good morning. I have a question on genetics here. Perhaps focusing on the Americas. It is impacted by the exits as you have reported, but if we dig a little bit closer into the report, you report the gross numbers, even excluding those exits. So it seems to be -3% instead of -4%. I am just struggling to understand a little bit about the U.S. growth in genetics. Are you seeing any kind of acceleration and did it actually grow in this quarter?
Genetics in North America absolutely grew in this quarter. We are doing really well there and have been for several quarters now. So North America is in very good shape. But we are exiting low-profit accounts in South America. That is a fact. So in genetics, South America is significantly down. It is a strategic decision. It is low-profit accounts. There are generic low-cost competitors coming in. We are not going to follow the market down. We have a lot of opportunities in Consumables and in technologies in South America. We prefer to focus our team's efforts on accelerating the growth there, which they absolutely did in the quarter. Other than focusing on low-profit genetics accounts. But I can tell you, Philip, we don't give the breakdown. But North America is performing very nicely in genetics. Yeah.
Okay. Thanks for that. And then perhaps a follow-up to the previous question that Ludwig asked as well, just in general on genetics. So organic growth is still negative across the company, even when excluding the exited business. So I'm just curious what is the path back to growth for this area?
Yeah. So, it is all going to be about focus. And I don't think we should look at specific products or specific tests. What we want to do is advance the growth of the Vitrolife AB Group company across the entire portfolio. If we believe we can accelerate faster in certain areas, which we do, that is where we will double down. But it is very much a portfolio play. What we're not going to do is stay in low-profit tests, low-profit markets, and low-profit customer accounts; we are not going to do that. The name of the game for our company is driving sustainable, profitable growth. So, to Pär's earlier point, our commercial excellence is much more sophisticated now. So we have been building pricing muscle. Our visibility is really good. It has been improving all the time. So this allows us to segment the market in a much more sophisticated way. As I mentioned during one of my slides in genetics, we have premium products and differentiated technology. We are a full-service provider. And that comes with premium prices. And that is where we will drive our growth. We will drive our growth in the premium segments of the genetic services market, not in the lower cost segment.
Okay.
Thank you.
Thank you so much.
Thanks, Philip. No.
The next question comes from Elvin Roleder from DNB Carnegie. Please go ahead.
Hello and good morning to you, Bronwyn and Pär. I have two questions here as well. Perhaps beginning a bit on China, considering your comments about IVF cycle activity in the region and in the upcoming years. What are your expectations regarding price levels in China in the coming years? Do you fear that pricing levels will fall, given that the clinics will have to fight for fewer cycles, or that vendors to the clinics will become more aggressive in pricing and defending their utilization? Can you give some comments about that and how we should think of gross margins in China as well?
That is a great question. Thank you. So as I mentioned, I am just back from China. I spent some time there to really understand the market dynamics. Our prices are actually performing very well in China. In fact, we have achieved price gains in China. We feel confident about being able to protect those prices because we have very strong share. We have a really good reputation for quality among Chinese clinics. Everything in IVF is about success rates. That is what it is all about. And in order to drive and increase your success rates, clinics typically like to use premium, proven quality products. And China is no different. So, we do not feel price pressure in China in the segments where we play. I would anticipate there will be an increase in price competition in the more commoditized areas. But for EmbryoScope and for media and for needles where we also have a differentiated offering, we believe we can hold pretty firm on our pricing. So, no expectations of a decline in the profitability of the China market. And I think you can see if you look at the gross margin and the contribution margin as Pär showed, we actually have a positive trend there. And we feel pretty good about that going forward.
Okay, great. Thank you. And then the second question relates to the exit of genetics in the South American markets. Are these markets or accounts that you are exiting also customers within your consumables branch? And have they been using both the genetics and consumables portfolio from Vitrolife AB? And if so, how are they responding to this decision to discontinue the genetics segment in these markets?
Yeah. So it is a bit of a combination.
To be honest.
Honest.
So we have some customers who use our EmbryoScope, our consumables, and our genetic services. But it is a bit of a mixed bag. I would say overall in South America, it's probably the region where we have one of the lower levels of complete portfolio purchasing. So there are other parts of the world, primarily where you tend to have, you know, I don't want to say full Vitrolife AB users, but higher total Vitrolife AB utilization. So in South America, we do have a lot of large accounts that have been primarily using genetic services and not necessarily users of consumables and technologies. But, the lower levels of profitability—Pär, you can comment on this as well—are specific to South America. We have had this for a while. We have been carrying this for a while. And so, I guess the lower-cost competitors entering the market just accelerates our decision not to play in lower-profit accounts. We have a lot of options. There is an opportunity cost to doing that. And look at our margins there; they are excellent. So, it does not make sense to have sales teams focusing on either driving growth or defending accounts that have really low levels of profitability when we have a really nice portfolio where we can drive much more profitable growth for our company and our shareholders. I do not know.
I think it is a combination of the situation in South America and our strategic decision not to play in low-profit accounts, but it is also because we have increased our ability and transparency of reviewing and analyzing our profitability on account level, market level, and customer level and so on. So it has led to our strategic decision to step away from low margin business.
Thank you so much for taking my questions. I will get back in the queue.
The next question comes from Carlos Moreno from Premier Miton. Please go ahead.
Hello. I just want to pull together what we've been talking about in the previous few questions. It just seems that you presented the greater than 10% top line targets at the end of 2023. And yet it seems you are falling short, albeit slowly. And it just seems that you've totally changed the strategy to one of very low top line organic growth, if any, and for all the good reasons, it's a nicely profitable business with high profitability. It seems that over the next five years, we are almost waiting for the new chief executive to tell us this, right? That is the organic growth for the business. It is a nice business. Vitrolife AB. But there isn't going to be much organic growth because you're going to get constant pressure on the low end of the market. Genetics. And you know, cycle growth is just not going to be that strong. You know, China has got issues. That is a big market. I just feel very frustrated as a shareholder. We are basically in at least a 12-month limbo before we have new targets that are going to look very different to the old targets. And it feels slightly odd that the greater than 10% targets were ever presented. I. I do not quite know. It is a bit of a big question. I just feel very frustrated. Yeah. Anyway, that is my question.
Okay. I can start. No, the targets are set by the board. They are now into the third year. The underlying assumption on organic growth was between 5% and 7% market growth. And us taking market shares on top of that. And as you have clearly seen recently, we are not there. We are not on a 5 to 7% underlying market growth. And then, of course, it is a challenge to be at 10% organic growth right now; if the market comes back to those underlying market growth levels, then we have a good chance to reach 10%. But in this quarter, we are far off, of course, with the softening in the market.
Yeah, I guess the only point that I would add, Carlos, is that those targets were set to the point that Pär made when IVF cycles were at higher levels. The market is soft right now. There is the situation in the Middle East. I think it is very clear what is happening in China. We know the macroeconomic situation is not good there. So the market is soft right now. We are driving profitable growth in the markets and in the areas of the portfolio where we see opportunities. And we are seeing that there is growth to be had. It is not the type of growth that we would want or our shareholders would want. So we are doubling down on the more profitable areas. That's that's a fact.
Yeah. It seems more structural than cyclical. It seems that the decision is to prioritize profitability and focus on the more profitable niches. And a lot of the big trends like China, they aren't. I mean, to say they're cyclical is a bit misleading really. They are medium-term, if not long-term, issues. And, unless there is a massive change in government strategy, such as significant reimbursement, which is unlikely, Vitrolife AB net top line growth will be limited over the next five years, it is as simple as that. It is just very odd to have such a mismatch between the reality and the targets set by the company. But anyway.
I think there are very wide regional variations.
Wide regional variations. Carlos, to your point, China definitely appears structural for sure. And North America has shown very positive green shoots. But you know, the geopolitics there make it very volatile. Western Europe is performing consistently. But there are parts of the world that clearly have structural issues, and then there are opportunities in other parts. China is the largest IVF market in the world in terms of cycles. So it does have an impact on the global cycles when demand is soft there.
Thanks.
Thank you, Carlos.
The next question comes from Jakob Lemke from Seb. Please go ahead.
Yes, thank you. I have a few more questions. I will start on the work you are doing with restructuring and discontinuation of products and countries. And on the sales line. It seems like the impact here in Q2 is a bit smaller than you communicated. I think the impact was 11 million in the quarter. And I think based on what you have said before, it should have been more like 20. So have you discontinued all the tests, or is there more to come going forward?
Yes, we have discontinued all the tests as we communicated in December. We will have an impact of 2% to 3%. And it had an impact of 2% in the second quarter. So from a percentage point of view, it is in line with what we communicated in December. So it is according to our expectation.
Okay. So there is no more revenue that is going to be impacted going forward.
No, we have completely exited those two tests. We are not performing them any longer. I think the last one we did was at the end of Q1.
Okay. Then on the savings part. I am wondering how much you have realized here in Q2. And also if you are at sort of full run rate exiting Q2.
Yeah. No, we are not at full run rate yet. We communicated a restructuring program with a restructuring reserve of 55 million, and we have consumed more or less half of that. We will continue into Q3 to execute on the planned restructuring. But we are in line with our plans. And we will most likely finish according to plan also by the end of Q3 as we have communicated. So the full saving of 65 MSEK on an annual basis will be reached. But on the other side, we will also continue to invest in our key markets and key functions and IT, offsetting some of that 65 MSEK. So you cannot expect to see a 65 MSEK reduction or improved EBITDA, because at the same time we are also investing in prioritized areas, but we are in line with the restructuring plans.
Okay, good. And then I'm also wondering which P&L line that reversal is in?
It is in the other operating income expense.
Yeah.
Okay, good. And then maybe a final question. Also, if you can comment on how much earnings gain you get year over year from the timing of the ESHRE conference, which I think is in Q3 this year. It was in Q2.
Yeah, I think the effect is 5 MSEK that we took in June last year, but we did not take this year in June because of timing.
Okay, good. Thank you.
As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.
So thank you all for dialing in. Hopefully, we have been able to answer most of your questions. If you do have any questions, you can follow up with our investor relations team. We wish you all a very nice summer from everyone here at the Vitrolife AB Group. Thank you very much.
Thank you.



















